MCID: FML039
MIFTS: 36

Female Reproductive System Disease

Categories: Reproductive diseases

Aliases & Classifications for Female Reproductive System Disease

MalaCards integrated aliases for Female Reproductive System Disease:

Name: Female Reproductive System Disease 12 15 17
Female Reproductive System Disorder 70
Genital Diseases, Female 44

Classifications:



External Ids:

Disease Ontology 12 DOID:229
ICD9CM 34 629.9
MeSH 44 D005831
SNOMED-CT 67 38233001
UMLS 70 C0017411 C0236100

Summaries for Female Reproductive System Disease

Disease Ontology : 12 A reproductive system disease that impairs the ability to reproduce and is located in the uterus, vagina, cervix, ovaries or fallopian tubes.

MalaCards based summary : Female Reproductive System Disease, also known as female reproductive system disorder, is related to uterine anomalies and endometriosis, and has symptoms including menometrorrhagia, mastodynia and breast engorgement. An important gene associated with Female Reproductive System Disease is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are MicroRNAs in cancer and miRNA targets in ECM and membrane receptors. The drugs Paclitaxel and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include uterus, cervix and breast.

Wikipedia : 73 The female reproductive system is made up of the internal and external sex organs that function in... more...

Related Diseases for Female Reproductive System Disease

Diseases related to Female Reproductive System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 221)
# Related Disease Score Top Affiliating Genes
1 uterine anomalies 32.7 MIR9-1 MIR518D MIR34A MIR30A MIR27A MIR214
2 endometriosis 32.7 MIR200B MIR200A MIR199A1 MIR145 MIR143 MIR141
3 endometriosis of ovary 32.7 MIR9-1 MIR145 MIR141
4 preterm premature rupture of the membranes 11.2
5 ectopic pregnancy 11.2
6 pelvic inflammatory disease 11.2
7 fallopian tube endometriosis 11.2
8 endosalpingiosis 11.2
9 endometriosis of intestine 11.2
10 endometriosis of pelvic peritoneum 11.2
11 endometriosis in scar of skin 11.2
12 endometriosis of rectovaginal septum and vagina 11.2
13 vaginal disease 11.2
14 hernia of ovary and fallopian tube 11.2
15 prolapse of female genital organ 11.2
16 amenorrhea 11.2
17 masters-allen syndrome 11.2
18 fallopian tube disease 11.2
19 vulvar disease 11.2
20 vulvovaginitis 11.2
21 gynatresia 11.2
22 parovarian cyst 11.2
23 bartholin's gland disease 11.2
24 bartholin's duct cyst 11.2
25 bile duct adenocarcinoma 10.7 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
26 glucose metabolism disease 10.7 MIR9-1 MIR30A MIR27A MIR21 MIR199A1 MIR196A1
27 ovary epithelial cancer 10.7 MIR9-1 MIR30A MIR21 MIR200A MIR199A1 MIR196A1
28 malignant ovarian surface epithelial-stromal neoplasm 10.7 MIR9-1 MIR30A MIR21 MIR200A MIR199A1 MIR196A1
29 central nervous system cancer 10.7 MIR9-1 MIR34A MIR30A MIR21 MIR199A1 MIR196A1
30 ovarian serous carcinoma 10.7 MIR27A MIR214 MIR21 MIR200B MIR200A MIR199A1
31 cell type benign neoplasm 10.7 MIR30A MIR21 MIR200A MIR199A1 MIR196A1 MIR193A
32 autoimmune disease of musculoskeletal system 10.7 MIR34A MIR30A MIR27A MIR21 MIR199A1 MIR196A1
33 leukocyte disease 10.7 MIR30A MIR27A MIR21 MIR200B MIR199A1 MIR196A1
34 squamous cell carcinoma, head and neck 10.7 MIR9-1 MIR214 MIR21 MIR205 MIR200A MIR199A1
35 bone marrow cancer 10.7 MIR9-1 MIR34A MIR30A MIR27A MIR21 MIR199A1
36 ovarian disease 10.7 MIR9-1 MIR30A MIR27A MIR21 MIR200B MIR200A
37 disease by infectious agent 10.7 MIR9-1 MIR34A MIR30A MIR27A MIR214 MIR21
38 intestinal benign neoplasm 10.7 MIR21 MIR199A1 MIR196A1 MIR17 MIR145 MIR143
39 sensory system disease 10.7 MIR9-1 MIR30A MIR27A MIR214 MIR21 MIR199A1
40 central nervous system disease 10.7 MIR9-1 MIR34A MIR30A MIR27A MIR21 MIR199A1
41 nervous system cancer 10.7 MIR9-1 MIR34A MIR30A MIR27A MIR214 MIR21
42 upper respiratory tract disease 10.7 MIR9-1 MIR30A MIR27A MIR21 MIR199A1 MIR196A1
43 acquired metabolic disease 10.7 MIR9-1 MIR34A MIR30A MIR27A MIR21 MIR200A
44 nasopharyngeal disease 10.7 MIR9-1 MIR30A MIR27A MIR21 MIR199A1 MIR196A1
45 arteries, anomalies of 10.7 MIR9-1 MIR34A MIR30A MIR27A MIR214 MIR21
46 autonomic nervous system neoplasm 10.7 MIR9-1 MIR34A MIR30A MIR27A MIR21 MIR199A1
47 pharynx cancer 10.7 MIR9-1 MIR30A MIR27A MIR21 MIR199A1 MIR196A1
48 oral cavity cancer 10.7 MIR9-1 MIR30A MIR21 MIR205 MIR199A1 MIR196A1
49 peripheral nervous system neoplasm 10.7 MIR9-1 MIR34A MIR30A MIR27A MIR21 MIR199A1
50 esophageal disease 10.7 MIR34A MIR30A MIR21 MIR200B MIR200A MIR199A1

Graphical network of the top 20 diseases related to Female Reproductive System Disease:



Diseases related to Female Reproductive System Disease

Symptoms & Phenotypes for Female Reproductive System Disease

UMLS symptoms related to Female Reproductive System Disease:


menometrorrhagia; mastodynia; breast engorgement; nipple discharge; leukorrhea; vaginal pruritus; vaginal odor; vaginal discomfort; pruritus vulvae; genital itching; perineal pain female; genitalia external painful; menopausal symptoms; vaginal pain; burning feeling vagina; mastoscirrhus; discomfort of vulva

Drugs & Therapeutics for Female Reproductive System Disease

Drugs for Female Reproductive System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
2
Bevacizumab Approved, Investigational Phase 3 216974-75-3
3
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
4 Tubulin Modulators Phase 3
5 Angiogenesis Inhibitors Phase 3
6 Antineoplastic Agents, Immunological Phase 3
7 Antimitotic Agents Phase 3
8 Albumin-Bound Paclitaxel Phase 3
9
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
10
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
11
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
12 Antibiotics, Antitubercular Phase 2
13 Immunosuppressive Agents Phase 2
14 Anti-Bacterial Agents Phase 2
15 Immunologic Factors Phase 2
16 Anti-Infective Agents Phase 2
17 Antifungal Agents Phase 2
18
Heparin Approved, Investigational 9005-49-6 772 9812414
19
Nadroparin Approved, Investigational
20
Lidocaine Approved, Vet_approved 137-58-6 3676
21 insulin
22 Hormones
23 Insulin, Globin Zinc
24 calcium heparin
25 Anti-Arrhythmia Agents
26 Anesthetics
27 Sodium Channel Blockers
28 Anesthetics, Local
29 Diuretics, Potassium Sparing

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy : A Prospective, Randomized, Controlled Study Unknown status NCT02097446 Phase 3
2 A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Active, not recruiting NCT01462890 Phase 3 Paclitaxel;Carboplatin
3 Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma Completed NCT01460979 Phase 2 Temsirolimus
4 Effect of Metabolic Variations Upon the Activity of the Neuroendocrine Reproductive Axis in Normal Female Volunteers Completed NCT02233283
5 Effect of Total Salpingectomy During Conservative Hysterectomy for Benign Disease on Ovarian Function: Non Inferiority Randomized Controlled Trial Completed NCT01628432
6 Studio Pilota Farmacocinetico-clinico Sulla Somministrazione di Eparina a Basso Peso Molecolare e Dosaggio Sierico di HGF Nelle Pazienti Operate Affette da Patologie Ginecologiche Completed NCT01523652
7 The Effect of Buffered Lidocaine Versus Nonbuffered Lidocaine on Pain Scores During Infiltration for Vulvar Biopsies Completed NCT02698527 Non-Buffered Lidocaine;Buffered Lidocaine
8 A Long Term Follow up of Perigee Anterior Meshes Performed for Recurrent Prolapse Completed NCT02642835
9 Study of Ovarian Function and Gynecological Profile of Patients Carrying a Pathogenic Variant of the HNF1B Gene (GYN-HNF1) Not yet recruiting NCT04746053

Search NIH Clinical Center for Female Reproductive System Disease

Cochrane evidence based reviews: genital diseases, female

Genetic Tests for Female Reproductive System Disease

Anatomical Context for Female Reproductive System Disease

MalaCards organs/tissues related to Female Reproductive System Disease:

40
Uterus, Cervix, Breast

Publications for Female Reproductive System Disease

Articles related to Female Reproductive System Disease:

# Title Authors PMID Year
1
[Analysis on reproductive health status and influencing factors of female workers of pharmaceutical industry in Gansu province]. 61
22356709 2011

Variations for Female Reproductive System Disease

Expression for Female Reproductive System Disease

Search GEO for disease gene expression data for Female Reproductive System Disease.

Pathways for Female Reproductive System Disease

Pathways related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.96 MIR9-1 MIR34A MIR30A MIR27A MIR214 MIR21
2 10.77 MIR200B MIR200A MIR141
3 10.27 MIR199A1 MIR145

GO Terms for Female Reproductive System Disease

Cellular components related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 MIR30A MIR27A MIR21 MIR205 MIR199A1 MIR17
2 extracellular vesicle GO:1903561 9.17 MIR34A MIR30A MIR27A MIR214 MIR21 MIR193A

Biological processes related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.93 MIR34A MIR27A MIR214 MIR21 MIR200B MIR17
2 positive regulation of angiogenesis GO:0045766 9.87 MIR30A MIR21 MIR199A1 MIR143
3 negative regulation of cell migration GO:0030336 9.83 MIR9-1 MIR34A MIR214 MIR21 MIR145
4 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.77 MIR199A1 MIR196A1 MIR193A
5 positive regulation of blood vessel endothelial cell migration GO:0043536 9.76 MIR30A MIR200A MIR143
6 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.71 MIR21 MIR199A1 MIR145
7 negative regulation of angiogenesis GO:0016525 9.7 MIR34A MIR214 MIR21 MIR200B MIR193A MIR145
8 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.69 MIR34A MIR214 MIR21
9 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.67 MIR27A MIR199A1 MIR17
10 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.67 MIR27A MIR214 MIR21 MIR17
11 positive regulation of connective tissue replacement GO:1905205 9.65 MIR34A MIR214 MIR199A1
12 negative regulation of cardiac muscle hypertrophy GO:0010614 9.64 MIR21 MIR145
13 regulation of smooth muscle contraction GO:0006940 9.63 MIR145 MIR143
14 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.63 MIR34A MIR17
15 negative regulation of vascular wound healing GO:0061044 9.62 MIR34A MIR200B
16 angiotensin-activated signaling pathway GO:0038166 9.62 MIR145 MIR143
17 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.61 MIR27A MIR21
18 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.61 MIR21 MIR17
19 negative regulation of lamellipodium assembly GO:0010593 9.6 MIR214 MIR196A1
20 aorta smooth muscle tissue morphogenesis GO:0060414 9.58 MIR145 MIR143
21 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.58 MIR214 MIR199A1 MIR17
22 gene silencing by miRNA GO:0035195 9.58 MIR9-1 MIR518D MIR518A1 MIR34A MIR30A MIR27A
23 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.56 MIR17 MIR143
24 negative regulation of vascular endothelial growth factor production GO:1904046 9.56 MIR34A MIR205 MIR199A1 MIR17
25 regulation of phenotypic switching GO:1900239 9.55 MIR145 MIR143
26 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.52 MIR145 MIR143
27 positive regulation of metalloendopeptidase activity GO:1904685 9.5 MIR21 MIR205 MIR17
28 miRNA mediated inhibition of translation GO:0035278 9.5 MIR9-1 MIR27A MIR21 MIR205 MIR200B MIR17

Molecular functions related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.73 MIR9-1 MIR34A MIR30A MIR27A MIR21 MIR205
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.55 MIR9-1 MIR518A1 MIR34A MIR30A MIR27A MIR214

Sources for Female Reproductive System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....